Research

Hormonal

Specific GLP-1 receptor agonists, semaglutide and liraglutide, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking Semaglutide or Liraglutide, watch for signs of gallbladder problems, such as pain in the upper right abdomen, nausea, or fever. These drugs can slow down your gallbladder, so report any such symptoms to your doctor promptly.

ModerateSupportsMEDIUM confidence
semaglutide (ROR, 4.06; 95% CI, 3.76–4.39) and liraglutide (ROR, 3.88; 95% CI, 3.50–4.29) indicated a notable risk... Liraglutide was identified as posing the highest potential risk for 'biliary malignant tumors' (n = 19)... semaglutide was notably associated with a significant risk of 'biliary tract disorders' (n = 188) and 'infectious biliary disorders' (n = 196).
Long He et al. · Frontiers in Pharmacology · 2025

Why this rating

Based on pharmacovigilance data (FAERS), which indicates statistical signals but is prone to reporting bias.

Source

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

Long He et al. · Frontiers in Pharmacology · 2025

DOI 10.3389/fphar.2025.1509561

cohort · n=2215Cited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →